中医药调节肠道菌群治疗非酒精性脂肪肝临床与实验研究进展

Progress in Clinical and Experimental Studies on the Treatment of Nonalcoholic Fatty Liver by Regulating Intestinal Flora with TCM

非酒精性脂肪肝(nonalcoholic fatty liver disease,NAFLD)的治疗以控制饮食和改善生活方式为主,但患者依从性差,目前西医学尚缺乏疗效确切的治疗方法。肠道微生态在NAFLD的发生发展中发挥重要作用。中药可以通过调节肠道菌群治疗NAFLD,特别是有些药物以及自拟中药复方的研究已经取得了一定的进展,临床上也发挥了较好的疗效,但是缺乏深入而广泛的随机、双盲、前瞻性临床试验研究和将动物实验与临床试验相结合的研究。今后,应更深入探讨NAFLD的发病机制,发挥中医药的独特优势,与中医辨证论治相结合,为不同的患者提供个性化诊疗措施,为科研指导临床提供科学合理的理论依据,制定更加安全有效且规范的诊疗方案。

The treatment of nonalcoholic fatty liver disease(NAFLD) is mainly to control diet and improve life style,but the patients′ compliance is poor.At present,there is no effective therapy in western medicine.Intestinal microecology plays an important role in the development of NAFLD.TCM can treat NAFLD by regulating intestinal flora,especially some drugs and self-made TCM compound prescriptions have made some progress,and also achieved a better clinical effect,but there is a lack of in-depth and extensive randomized,double-blind,prospective clinical trial research and the combination of animal experiments and clinical trials.Therefore,in the future,it is necessary to further explore the pathogenesis of NAFLD,give full play to the unique advantages of TCM,combine with syndrome differentiation and treatment of TCM,provide personalized diagnosis and treatment measures for different patients,provide scientific and reasonable theoretical basis for research and clinical guidance,and formulate a more safe,effective and standardized diagnosis and treatment program.